Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $240.88 +1.33%
Revenue Growth %: +6.2%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +6.2%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
